See how top analysts and institutions rate CVS — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| Goldman | Initiated | Buy | $91 | 2025-10-14 |
| UBS | Upgrade | Neutral → Buy | $79 | 2025-08-18 |
| Robert W. Baird | Upgrade | Neutral → Outperform | $82 | 2025-08-14 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 6 | 17 | 5 | 0 | 0 |
| October 2025 | 6 | 17 | 5 | 0 | 0 |
| September 2025 | 7 | 16 | 4 | 0 | 0 |
| August 2025 | 7 | 15 | 5 | 0 | 0 |
The majority of institutional investors have issued a "Buy" rating for CVS, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
